Summary
64 / 100 · Bulios Score
What speaks for it
- It earns 21 USD a year on every 100 USD of invested capital.
- Revenue grew by 17% a year over the last 3 years.
- It holds more cash than debt: $89.8M against $35.2M.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 38.0 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 15% a year over 5 years. Over the last 3 years it grew by 17% a year. For the next fiscal year analysts expect revenue to fall by 0.5%. Earnings per share grew by 10% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 78 USD
- Sales and administration 15 USD
- Taxes and other 1.8 USD
- Net profit 4.5 USD
Net profit, industry median (Medical - Care Facilities) 6.7 USD
Out of every 100 USD of revenue, 4.5 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 4
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $50.67 is 28% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Corporate Segment 100%
By region
The company reports no revenue by region.
Corporate Segment brings in 100% of revenue.
Segments in detail